These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17439521)

  • 1. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
    Pillai V; Lee WM; Thiele DL; Karandikar NJ
    J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
    Caetano J; Martinho A; Paiva A; Pais B; Valente C; Luxo C
    J Virol; 2008 Aug; 82(15):7567-77. PubMed ID: 18480446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
    Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T
    Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
    Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
    Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
    Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P
    Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.
    Zhang Y; Liu Y; Zhao Y; Shi L; Ma L; Yan H; Wu H; Wei L; Dong T; Chen X
    Liver Int; 2012 Jan; 32(1):102-9. PubMed ID: 22098382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
    Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
    Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells.
    Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Márquez-Galán JL; Núñez-Roldán A; Aguilar-Reina J
    Liver Int; 2014 Jul; 34(6):e80-8. PubMed ID: 24127783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
    Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
    J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
    Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
    Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
    Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
    Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.
    Donlin MJ; Cannon NA; Aurora R; Li J; Wahed AS; Di Bisceglie AM; Tavis JE;
    PLoS One; 2010 Feb; 5(2):e9032. PubMed ID: 20140258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment.
    Silva JPCG; Jesus LS; Isabel Schinoni M; Oliveira IS; Atta MLBS; Atta AM
    Int Immunopharmacol; 2021 Apr; 93():107405. PubMed ID: 33529909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
    Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV genotype-3a T cell immunity: specificity, function and impact of therapy.
    Humphreys IS; von Delft A; Brown A; Hibbert L; Collier JD; Foster GR; Rahman M; Christian A; Klenerman P; Barnes E
    Gut; 2012 Nov; 61(11):1589-99. PubMed ID: 22337948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy.
    Tang KH; Herrmann E; Cooksley H; Tatman N; Chokshi S; Williams R; Zeuzem S; Naoumov NV
    J Hepatol; 2005 Nov; 43(5):776-82. PubMed ID: 16139918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.
    Rallón NI; Soriano V; Restrepo C; García-Samaniego J; Labarga P; López M; Peris A; González-Lahoz J; Benito JM
    J Acquir Immune Defic Syndr; 2011 May; 57(1):1-8. PubMed ID: 21786458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.
    Barnes E; Harcourt G; Brown D; Lucas M; Phillips R; Dusheiko G; Klenerman P
    Hepatology; 2002 Sep; 36(3):743-54. PubMed ID: 12198669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
    Prabdial-Sing N; Blackard JT; Puren AJ; Mahomed A; Abuelhassan W; Mahlangu J; Vermeulen M; Bowyer SM
    Antiviral Res; 2016 Mar; 127():90-8. PubMed ID: 26704023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.